Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.41 |
| ▸ | TLR4 | O00206 | 5/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083128 | 0.95 | TLR4 (0.37) | NAAAPAMLY96TLR4KMT2A | |
| SCHEMBL3083187 | 0.89 | ALDH1A1 (0.35) | LY96TLR4KMT2ATSHRALDH1A1 | |
| SCHEMBL8444060 | 0.89 | GPR55 (0.37) | NAAAPAMLY96TLR4GPR55 | |
| SCHEMBL3080744 | 0.85 | LY96 (0.47) | NAAALY96TLR4MAPTGPR55 | |
| SCHEMBL3063341 | 0.83 | LY96 (0.53) | NAAALY96TLR4 | |
| SCHEMBL3075893 | 0.83 | LY96 (0.53) | NAAALY96TLR4 | |
| SCHEMBL3085410 | 0.83 | MEN1 (0.34) | KMT2ATSHRTDP1MEN1 | |
| SCHEMBL3082731 | 0.81 | LY96 (0.55) | NAAALY96TLR4GPR55 | |
| SCHEMBL3075469 | 0.81 | LY96 (0.55) | NAAALY96TLR4GPR55 | |
| SCHEMBL3080244 | 0.80 | LY96 (0.43) | NAAALY96TLR4GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | PERSTORP AB (SE) | 2005-10-13 | — | — | US | disclosed |
| US-6949517-B1 | Method of treating inflammatory, tissue repair and infectious conditions | SIREN MATTI | 2005-09-27 | — | — | US | disclosed |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | BIONERIS AB (SE) | 2004-11-25 | — | — | US | disclosed |
| US-6632797-B2 | Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions | SIREN MATTI (FI) | 2003-10-14 | — | — | US | disclosed |
| EP-1216705-A2 | The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair | PERSTORP AB (SE) | 2002-06-26 | — | — | EP | disclosed |
| US-20020065253-A1 | Use of growth factor modulating compounds | SIREN MATTI (FI) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | NAAA 2602/4885PAM 299/4885LY96 3278/4885 |
| US-20020065253-A1 | Use of growth factor modulating compounds | HDGF, PGF, FGF2 | NAAA 4741/4885PAM 989/4885LY96 1810/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | NAAA 3151/4885PAM 829/4885LY96 865/4885 |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | PCNA, OPRK1, OGFR | NAAA 4255/4885PAM 235/4885LY96 3381/4885 |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | TNF, TLR2, TPMT | NAAA 4163/4885PAM 742/4885LY96 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.